Quantitative 99mTc-DPD-SPECT/CT assessment of cardiac amyloidosis

[1]  U. Eriksson,et al.  Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. , 2021, European heart journal.

[2]  P. Milani,et al.  Management of AL amyloidosis in 2020. , 2020, Blood.

[3]  R. Falk,et al.  Absolute Quantitation of Cardiac 99mTc-Pyrophosphate Using Cadmium-Zinc-Telluride–Based SPECT/CT , 2020, The Journal of Nuclear Medicine.

[4]  E. Klotz,et al.  DPD Quantification in Cardiac Amyloidosis , 2020, JACC. Cardiovascular imaging.

[5]  P. Haaf,et al.  Quantitative 99mTc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores , 2019, Journal of Nuclear Cardiology.

[6]  C. Rapezzi,et al.  Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. , 2019, Circulation. Heart failure.

[7]  Sanjiv J. Shah,et al.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI EXPERT CONSENSUS RECOMMENDATIONS FOR MULTIMODALITY IMAGING IN CARDIAC AMYLOIDOSIS: PART 1 OF 2-EVIDENCE BASE AND STANDARDIZED METHODS OF IMAGING. , 2019, Journal of cardiac failure.

[8]  C. Di Mario,et al.  Semi-quantitative indices of cardiac uptake in patients with suspected cardiac amyloidosis undergoing 99mTc-HMDP scintigraphy , 2019, Journal of Nuclear Cardiology.

[9]  Won Woo Lee,et al.  Maximum standardized uptake value of foot SPECT/CT using Tc-99m HDP in patients with accessory navicular bone as a predictor of surgical treatment , 2019, Medicine.

[10]  Youmin Guo,et al.  A retrospective study of SPECT/CT scans using SUV measurement of the normal pelvis with Tc-99m methylene diphosphonate. , 2018, Journal of X-ray science and technology.

[11]  P. Hawkins,et al.  Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[12]  M. Oyama,et al.  Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer , 2017, European Journal of Hybrid Imaging.

[13]  J. Dubois-Randé,et al.  Early Phase 99Tc-HMDP Scintigraphy for the Diagnosis and Typing of Cardiac Amyloidosis. , 2017, JACC. Cardiovascular imaging.

[14]  B. Bettencourt,et al.  Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis , 2016, Journal of Nuclear Cardiology.

[15]  J. Goldsmith,et al.  Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. , 2016, JAMA cardiology.

[16]  A. Dispenzieri,et al.  Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. , 2016, Journal of the American College of Cardiology.

[17]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[18]  A. Hagège,et al.  Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. , 2016, European heart journal.

[19]  E. González-López,et al.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.

[20]  Dale L. Bailey,et al.  Quantitative SPECT/CT: SPECT joins PET as a quantitative imaging modality , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  B. Hazenberg,et al.  Bone scintigraphy with 99mtechnetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[22]  M. Dimopoulos,et al.  A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. , 2013, Blood.

[23]  M. Maurer,et al.  99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses , 2013, Circulation. Cardiovascular imaging.

[24]  M. Dimopoulos,et al.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Tanabe,et al.  Novel method for quantitative evaluation of cardiac amyloidosis using 201TlCl and 99mTc-PYP SPECT , 2012, Annals of Nuclear Medicine.

[26]  D. Dingli,et al.  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  F. Salvi,et al.  Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. , 2005, Journal of the American College of Cardiology.

[28]  DPD Quanti fi cation in Cardiac Amyloidosis A Novel Imaging Biomarker , 2022 .